TRML

20.65

1.52% 0.31

Handel nachbörslich: 20.65

Tourmaline Bio Inc (TRML)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$20.34

Offen:

$20.22

24-Stunden-Volumen:

819.36K

Relative Volume:

3.45

Marktkapitalisierung:

$529.52M

Einnahmen:

Nettoeinkommen (Verlust:

$11.77M

KGV:

-133.48

EPS:

-0.1547

Netto-Cashflow:

$-19.23M

1W Leistung:

-5.32%

1M Leistung:

-13.96%

6M Leistung:

+36.66%

1J Leistung:

+8.68%

1-Tages-Spanne:

$20.20

$21.53

1-Wochen-Bereich:

$19.14

$22.80

52-Wochen-Spanne:

$12.12

$48.31

Tourmaline Bio Inc Stock (TRML) Company Profile

Firmenname

Tourmaline Bio Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

646-481-9832

Adresse

27 WEST 24TH STREET, NEW YORK

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TRML's Discussions on Twitter

Vergleichen Sie TRML mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TRML Tourmaline Bio Inc	20.65	529.52M	0	11.77M	-19.23M	0.5785
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-11-11	Bestätigt	H.C. Wainwright	Buy
2023-12-15	Eingeleitet	Jefferies	Buy
2023-12-04	Fortgesetzt	H.C. Wainwright	Buy
2023-11-17	Eingeleitet	Truist	Buy
2023-10-31	Eingeleitet	Guggenheim	Buy
2023-10-25	Eingeleitet	Piper Sandler	Overweight
2022-10-20	Eingeleitet	H.C. Wainwright	Buy
2022-07-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight

Alle ansehen

Tourmaline Bio Inc Aktie (TRML) Neueste Nachrichten

Dec 20, 2024

Fmr LLC Has $387,000 Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Dec 20, 2024

Graves Ophthalmopathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - EIN News

Dec 20, 2024

Dec 19, 2024

Wellington Management Group LLP Raises Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat

Dec 19, 2024

Dec 17, 2024

The Manufacturers Life Insurance Company Buys 5,945 Shares of Orchid Island Capital, Inc. (NYSE:ORC) - Defense World

Dec 17, 2024

The Manufacturers Life Insurance Company Takes $226,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Dec 17, 2024

Tourmaline Bio, Inc. (NASDAQ:TRML) Holdings Lifted by Charles Schwab Investment Management Inc. - Defense World

Dec 17, 2024

Dec 15, 2024

Northrim BanCorp, Inc. (NASDAQ:NRIM) Shares Sold by BNP Paribas Financial Markets - Defense World

Dec 15, 2024

BNP Paribas Financial Markets Sells 1,132 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Dec 15, 2024

BNP Paribas Financial Markets Sells 509 Shares of First Internet Bancorp (NASDAQ:INBK) - Defense World

Dec 15, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 74,430 Shares of The GEO Group, Inc. (NYSE:GEO) - Defense World

Dec 15, 2024

Dec 14, 2024

FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst - Defense World

Dec 14, 2024

Dec 13, 2024

Analysts Issue Forecasts for Tourmaline Bio FY2025 Earnings - MarketBeat

Dec 13, 2024

Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from HC Wainwright - Defense World

Dec 13, 2024

Dec 11, 2024

Tourmaline Bio's (TRML) Buy Rating Reiterated at HC Wainwright - MarketBeat

Dec 11, 2024

Tourmaline Bio expands trial and advisory board By Investing.com - Investing.com South Africa

Dec 11, 2024

Dec 10, 2024

Tourmaline Announces the Over-Enrollment of its Phase 2 TRANQUILITY Trial - Marketscreener.com

Dec 10, 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - The Manila Times

Dec 10, 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates - EIN News

Dec 10, 2024

Tourmaline Bio's TRANQUILITY Trial Surpasses Enrollment Target, Expands into Aortic Aneurysm Treatment - StockTitan

Dec 10, 2024

Dec 09, 2024

Tourmaline Bio to host investor day - MSN

Dec 09, 2024

Critical Analysis: Burford Capital (NYSE:BUR) & MARA (NASDAQ:MARA) - Defense World

Dec 09, 2024

Dec 08, 2024

338,437 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Bought by Point72 Asset Management L.P. - MarketBeat

Dec 08, 2024

BMO Capital Markets Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - Defense World

Dec 08, 2024

Dec 06, 2024

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.25 Consensus Target Price from Analysts - MarketBeat

Dec 06, 2024

Dec 04, 2024

Likelihood of Approval and Phase Transition Success Rate ModelPacibekitug in Atherosclerosis - GlobalData

Dec 04, 2024

Dec 02, 2024

Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR

Dec 02, 2024

Nov 28, 2024

Tourmaline Bio, Inc. (NASDAQ:TRML) is Acuta Capital Partners LLC's 3rd Largest Position - MarketBeat

Nov 28, 2024

Nov 22, 2024

Jennison Associates LLC Has $29.62 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat

Nov 22, 2024

Nov 18, 2024

Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 - InvisionMag

Nov 18, 2024

Nov 17, 2024

This Week in Ophthalmology: Week of November 11, 2024 - Ophthalmology Times

Nov 17, 2024

Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Tourmaline Bio Inc - GuruFocus.com

Nov 15, 2024

HC Wainwright Reduces Earnings Estimates for Tourmaline Bio - Defense World

Nov 15, 2024

Nov 14, 2024

HC Wainwright Lowers Earnings Estimates for Tourmaline Bio - MarketBeat

Nov 14, 2024

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - The Manila Times

Nov 14, 2024

Midland Identifies Gold Potential on Its Caniapisc Au Project, James Bay - The Manila Times

Nov 14, 2024

Tourmaline Bio Sets Key Investor Day with Focus on Pacibekitug Development | TRML Stock News - StockTitan

Nov 14, 2024

Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Significant Decrease in Short Interest - Defense World

Nov 14, 2024

Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) Short Interest Update - Defense World

Nov 14, 2024

Short Interest in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCYW) Decreases By 97.6% - Defense World

Nov 14, 2024

TruBridge (NASDAQ:TBRG) Price Target Raised to $14.00 - Defense World

Nov 14, 2024

Greenlane Renewables (OTCMKTS:GRNWF) Trading 21.2% Higher – Here’s What Happened - Defense World

Nov 14, 2024

Nov 13, 2024

Global Healthcare & Medical Tourism News - Medical Tourism Magazine

Nov 13, 2024

Nov 12, 2024

Tourmaline Bio ATM - SVB Leerink

Nov 12, 2024

Varonis Systems, Inc. (NASDAQ:VRNS) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Nov 12, 2024

Tourmaline stock PT nudged by H.C. Wainwright, citing confidence in pacibekitug - Investing.com UK

Nov 12, 2024

Nov 11, 2024

Tourmaline Bio, Inc. Reports Third Quarter Financial Results - TipRanks

Nov 11, 2024

Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC Wainwright - MarketBeat

Nov 11, 2024

Nov 07, 2024